Tymora Analytical Operations LLC is structured to provide diagnostic development and exosome proteomics contract services and products for improved cancer research. Wiith a primary objective being to enable the shift from tissue to liquid biopsy, the firms new technologies allow detection of active exosome protein and phosphoprotein cancer markers directly from plasma, urine or saliva. As a platform to discover, validate and routinely detect diagnostic markers, the firm's approach offers important potential to find signaling proteins in biofluids that were not previously accessible. Designed to provide novel, highly-effective and cost-efficient approaches to carrying out proteomic and phosphorylation analyses, Tymora is undertaking further development new applications of the technologies. The firm is receptive to collaborations with partners interested in Tymora's technology for design and validation of early disease detection tests, cancer monitoring post-treatment, or for companion diagnostic assays for pipeline therapies.
